ECSP11011439A - Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 - Google Patents

Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750

Info

Publication number
ECSP11011439A
ECSP11011439A EC2011011439A ECSP11011439A ECSP11011439A EC SP11011439 A ECSP11011439 A EC SP11011439A EC 2011011439 A EC2011011439 A EC 2011011439A EC SP11011439 A ECSP11011439 A EC SP11011439A EC SP11011439 A ECSP11011439 A EC SP11011439A
Authority
EC
Ecuador
Prior art keywords
compounds
cyanoethylethyclic
carboxamide
substituted
therapy
Prior art date
Application number
EC2011011439A
Other languages
English (en)
Inventor
Antonio Mete
Rhonan Ford
Andrew Mather
Ian Millichip
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP11011439A publication Critical patent/ECSP11011439A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I), donde y, m, n, R1, R2 y Q son como se definen en la descripción, un proceso para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia.
EC2011011439A 2009-05-07 2011-11-07 Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750 ECSP11011439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17627909P 2009-05-07 2009-05-07
US18562909P 2009-06-10 2009-06-10

Publications (1)

Publication Number Publication Date
ECSP11011439A true ECSP11011439A (es) 2011-12-30

Family

ID=42271991

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011439A ECSP11011439A (es) 2009-05-07 2011-11-07 Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750

Country Status (22)

Country Link
US (2) US8193239B2 (es)
EP (1) EP2427445A1 (es)
JP (1) JP2012526093A (es)
KR (1) KR20120034639A (es)
CN (1) CN102574830A (es)
AR (1) AR076551A1 (es)
AU (1) AU2010244218B2 (es)
BR (1) BRPI1015540A2 (es)
CA (1) CA2759581A1 (es)
CL (1) CL2011002787A1 (es)
CO (1) CO6450612A2 (es)
CR (1) CR20110579A (es)
CU (1) CU20110204A7 (es)
EA (1) EA201190235A1 (es)
EC (1) ECSP11011439A (es)
IL (1) IL215615A0 (es)
MX (1) MX2011011661A (es)
SG (1) SG175090A1 (es)
TW (1) TW201041889A (es)
UY (1) UY32611A (es)
WO (1) WO2010128324A1 (es)
ZA (1) ZA201108962B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668775T3 (es) 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
EP2606886B1 (en) 2010-08-20 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
US8841463B2 (en) * 2011-02-11 2014-09-23 Glaxosmithkline Intellectual Property Development Limited Cathepsin C inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
PL2902029T3 (pl) 2012-09-25 2019-01-31 Chugai Seiyaku Kabushiki Kaisha Inhibitor RET
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
JP6441830B2 (ja) * 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
EP2970252B1 (en) 2013-03-14 2020-06-03 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP6437929B2 (ja) * 2013-03-14 2018-12-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
EP3013810A1 (en) 2013-06-24 2016-05-04 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
CN105612149A (zh) * 2013-09-09 2016-05-25 普罗技迈克斯公司 作为二肽基肽酶i抑制剂的肽基腈化合物
NO2699580T3 (es) 2014-01-24 2018-02-24
WO2015163448A1 (ja) 2014-04-25 2015-10-29 中外製薬株式会社 ４環性化合物を高用量含有する製剤
RU2016146119A (ru) 2014-04-25 2018-05-29 Чугаи Сейяку Кабусики Кайся Новый кристалл тетрациклического соединения
EP3154979B1 (en) 2014-06-12 2018-03-07 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
WO2016016242A1 (en) 2014-08-01 2016-02-04 Boehringer Ingelheim International Gmbh Substituted oxetanes and their use as inhibitors of cathepsin c
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
TWI752901B (zh) 2015-01-16 2022-01-21 日商中外製藥股份有限公司 合併用醫藥
DK3265452T3 (en) * 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2016139355A1 (en) 2015-03-05 2016-09-09 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
CN106478629A (zh) * 2015-08-24 2017-03-08 上海医药工业研究院 一种利格列汀的制备工艺
AU2017226005A1 (en) 2016-03-01 2018-09-06 Propellon Therapeutics Inc. Inhibitors of WDR5 protein-protein binding
US11319299B2 (en) 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
PT3758708T (pt) 2018-03-01 2025-02-13 Astrazeneca Ab Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
BR112020025499A2 (pt) 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
WO2020018551A1 (en) * 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
TWI825163B (zh) 2018-09-04 2023-12-11 日商中外製藥股份有限公司 四環性化合物的製造方法
PL4129989T3 (pl) 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
KR20230117738A (ko) 2020-12-04 2023-08-09 레이스톤 바이오파마 컴퍼니 리미티드 카텝신 c의 소분자 억제제 및 이의 의약적 용도
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
JP2025506307A (ja) * 2022-02-22 2025-03-07 ハイスコ ファーマスーティカル プライベート リミテッド 含窒素複素環化合物の調製方法
US20250361226A1 (en) 2022-06-07 2025-11-27 Reistone Biopharma Company Limited Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
TW202404960A (zh) 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的多晶型及其製備方法和用途
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途
KR20260093304A (ko) * 2023-09-15 2026-06-19 인스메드 인코포레이티드 디펩티딜 펩티다제 1 억제제 및 이의 용도
WO2025165806A1 (en) * 2024-01-29 2025-08-07 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
DE60028045T2 (de) 1999-07-30 2007-02-15 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Neue bernsteinsäure derivative als cysteine-protease-inhibitoren
ATE339404T1 (de) 1999-12-24 2006-10-15 Hoffmann La Roche Nitrilderivate als cathepsin k hemmer
ATE370943T1 (de) 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
ATE469645T1 (de) * 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
WO2004110988A1 (en) * 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases

Also Published As

Publication number Publication date
EP2427445A1 (en) 2012-03-14
CA2759581A1 (en) 2010-11-11
AR076551A1 (es) 2011-06-22
WO2010128324A1 (en) 2010-11-11
ZA201108962B (en) 2012-08-29
AU2010244218B2 (en) 2012-07-19
SG175090A1 (en) 2011-11-28
CL2011002787A1 (es) 2012-06-22
US20100286118A1 (en) 2010-11-11
US20120329775A1 (en) 2012-12-27
CR20110579A (es) 2012-01-09
US8193239B2 (en) 2012-06-05
UY32611A (es) 2010-12-31
IL215615A0 (en) 2011-12-29
BRPI1015540A2 (pt) 2019-09-24
EA201190235A1 (ru) 2012-05-30
JP2012526093A (ja) 2012-10-25
TW201041889A (en) 2010-12-01
MX2011011661A (es) 2011-11-18
CO6450612A2 (es) 2012-05-31
CU20110204A7 (es) 2012-03-15
KR20120034639A (ko) 2012-04-12
AU2010244218A1 (en) 2011-11-03
CN102574830A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY31524A1 (es) Nuevos compuestos 010
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR11861A (es) Compuestos organicos
CR11623A (es) Compuestos
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
BR112012029647A2 (pt) novos derivados de pirimidinas
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR20110309A (es) Compuestos orgánicos
CR20120264A (es) Compuestos
ECSP14013215A (es) Compuestos novedosos
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
UY32918A (es) Nuevos compuestos de 2-piridona
NI201500050A (es) Benzamidas
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
ECSP099679A (es) Nuevos compuestos y sus usos 707
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75